# The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)

> **NCT00441584** · PHASE3 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 117 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **BIOLOGICAL:** PegIntron (peginterferon alfa-2b)
- **DRUG:** Rebetol (ribavirin)

## Key facts

- **NCT ID:** NCT00441584
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-07
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 117 (ACTUAL)
- **Why stopped:** Subject accrual was prematurely terminated due slow enrollment.
- **Last updated:** 2017-04-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00441584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00441584, "The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00441584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*